Senseonics (NYSE:SENS) Posts Earnings Results, Misses Expectations By $0.09 EPS

Senseonics (NYSE:SENS) issued its quarterly earnings data on Monday. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.09), RTT News reports. Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. During the same period in the previous year, the firm earned ($0.07) EPS. Senseonics updated its FY 2025 guidance to EPS.

Senseonics Stock Performance

Shares of NYSE:SENS opened at $0.87 on Tuesday. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The business’s 50 day moving average price is $0.85 and its 200-day moving average price is $0.53. The firm has a market capitalization of $517.93 million, a PE ratio of -6.69 and a beta of 0.69. Senseonics has a 1 year low of $0.25 and a 1 year high of $1.40.

Insiders Place Their Bets

In other news, CFO Frederick T. Sullivan acquired 124,933 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $0.38 per share, for a total transaction of $47,474.54. Following the acquisition, the chief financial officer now owns 2,478,844 shares of the company’s stock, valued at $941,960.72. This represents a 5.31 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Timothy T. Goodnow acquired 315,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was purchased at an average price of $0.31 per share, for a total transaction of $97,650.00. Following the acquisition, the chief executive officer now directly owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

SENS has been the topic of several recent analyst reports. StockNews.com started coverage on Senseonics in a research report on Thursday, December 26th. They set a “sell” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Senseonics in a report on Friday, November 15th.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.